Spondyloarthritis & psoriatic arthritis
Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis
Authors' conclusion
Concomitant IBD is associated with impaired treatment response and greater residual symptom burden in PsA
Study context
- Population
- Psoriatic arthritis (PsA) patients initiating TNF inhibitors or anti-IL-12/23 agents between 2011 and 2023matched cohort
- Participants
- 120 patients
- Exposure
- PsA with concomitant inflammatory bowel disease (IBD) vs PsA without IBD, initiating TNFi or anti-IL-12/23 agents
- PsA-IBDn = 60
- Only-PsAn = 60reference
- Outcome
- Predictors of achieving minimal disease activity (MDA) and DAPSA remission or low disease activity (LDA)
- Follow-up
- 6 months
Methodological detailsmatched for age, sex, disease duration and biologic class, multivariable logistic regression
- Matched for age, sex, disease duration and biologic class
- Multivariable logistic regression
Main finding
As reported in the abstract
PsA-IBD vs Only-PsAEstimate (95 % CI)P value
IBD independently predicted lower odds of MDA
aOR for achieving MDA (IBD as predictor) 0.28(0.11–0.69)
P = 0.006Borderline association with reduced DAPSA response
aOR for achieving DAPSA remission/LDA (IBD as predictor) 0.39(0.15–1.02)
P = 0.055Observational data: associations, not effects.
Secondary outcomes
VAS pain, PtGA and HAQ-DI · 12 months
- PsA-IBD reported persistently higher VAS pain, PtGA and HAQ-DI scores despite objective clinical improvements
Original publication
Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis. Semin Arthritis Rheum. Published 6 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →